Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. Sold as Plaquenil, Sovuna. Every FDA application for this active ingredient: 2 branded and 15 generic.
As of Nov 15, 2026, FDA lists 17 applications for Hydroxychloroquine Sulfate (sold as Plaquenil, Sovuna), first approved Apr 18, 1955, with 0 new uses approved and 1 published complete response letter.
First approved: Apr 18, 1955
Applications: 17
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $106M
First approved in Japan: Jul 3, 2015
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 722 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Plaquenil, new ingredientA drug with a new active ingredient indicated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. · Sanofi K.K. · Jul 3, 2015
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA